Document is current
Any future updates will be listed below
-
Authors
Damgaard, Viktoria https://orcid.org/0000-0002-4257-3136
Schandorff, Johanna Mariegaard
Macoveanu, Julian https://orcid.org/0000-0001-6148-9477
Sankar, Anjali https://orcid.org/0000-0002-7517-9776
Zarp, Jeff https://orcid.org/0000-0002-3415-8098
Fisher, Patrick M. https://orcid.org/0000-0002-8115-0611
Jørgensen, Martin Balslev https://orcid.org/0000-0002-1321-8901
Kessing, Lars Vedel https://orcid.org/0000-0001-9377-9436
Knudsen, Gitte Moos https://orcid.org/0000-0003-1508-6866
Frokjaer, Vibe G.
Miskowiak, Kamilla Woznica https://orcid.org/0000-0003-2572-1384
- License Information
-
More Information
Article History
Received: 12 March 2024
Revised: 13 May 2025
Accepted: 4 June 2025
First Online: 17 June 2025
Competing interests
: KWM has received honoraria from Lundbeck, Janssen-Cilag, Angelini and Gedeon Richter in the past three years. LVK has been a consultant for Teva and Lundbeck during recent three years. JZ has within the last three years received honoraria from Lundbeck Pharma A/S. GMK has been a speaker or consultant for several pharmaceutical companies, all unrelated to the present study. VGF has received honoraria for lectures from Sage Therapeutics, Gedeon-Richter A/S, Janssen-Cilag A/S, Lundbeck Pharma A/S. The remaining authors declare no conflict of interest.
: All methods in this study were performed in accordance with the relevant guidelines and regulations, including the declaration of Helsinki. Approval was obtained from the Danish Research Ethics Committee for the Capital Region of Denmark (BIO: H-72014007; PRETEC-EPO: H-16043370; PRETEC-ABC: H-16043480) and The Danish Data Protection Agency Capital Region of Denmark (BIO: RHP-2015-023; PRETEC: 2012-58-0004). Informed consent was obtained from all participants prior to participation in their respective studies.
